Эффективность a-липоевой кислоты при диабетической полинейропатии

Обложка

Цитировать

Полный текст

Аннотация

Диабетическая полинейропатия (ДПН) является серьезным осложнением сахарного диабета. Целью данного обзора является оценка эффективности и безопасности a-липоевой кислоты (AЛК, тиоктовой кислоты) в лечении ДПН. АЛК является эффективным средством лечения ДПН, сочетая выраженное и быстрое антиноцицептивное действие с отсроченными патогенетическими эффектами. В клинической практике АЛК может быть препаратом выбора у больных с симптомной ДПН в сочетании с легким и умеренным сенсорным дефицитом, а также при сочетании ДПН с поражением вегетативной нервной системы.

Об авторах

Владимир Николаевич Храмилин

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России

Email: Khramilin_RGMU@mail.ru
канд. мед. наук, доц. каф. эндокринологии и диабетологии ФДПО ГБОУ ВПО РНИМУ им.Н.И.Пирогова 117997, Россия, Москва, ул. Островитянова, д. 1

Валерия Александровна Андреева

ГБОУ ВПО Российский национальный исследовательский медицинский университет им. Н.И.Пирогова Минздрава России

аспирант каф. эндокринологии и диабетологии ФДПО ГБОУ ВПО РНИМУ им.Н.И.Пирогова 117997, Россия, Москва, ул. Островитянова, д. 1

Список литературы

  1. Бреговский В.Б., Посохина О.В., Карпова И.А. Предикторы эффективности лечения диабетической полинейропатии нижних конечностей альфа - липоевой кислотой. Терапевт. архив. 2005; 10: 15-9.
  2. Храмилин В.Н., Андреева В.А., Демидова И.Ю. Комбинированная терапия болевой диабетической полинейропатии: результаты пилотного исследования. Фарматека. 2014; 16: 48-53.
  3. Храмилин В.Н., Демидова И.Ю., Игнатова О.Ю. Оценка эффективности различных режимов пероральной терапии альфа - липоевой кислотой болевой формы диабетической периферической полинейропатии. Сахарный диабет. 2010; 2: 3-7.
  4. Ametov A, Barinov A, O’Brien P et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha lipoic acid. The SYDNEY Trial. Diabetes Care 2003; 26: 770-6.
  5. Androne L, Gavan N.A, Veresiu I.A, Orasan R. In vivo effect of lipoic acid on lipid peroxidation in patients with diabetic neuropathy. In Vivo 2000; 14: 327-30.
  6. Antonoglou C, Papanas N, Maltezos E. Lipid - lowering therapy in the diabetic foot: seeing the whole iceberg and not just the tip. Curr Vasc Pharmacol 2012. [Epub ahead of print].
  7. Available from: http://pubchem.ncbi.nlm. nih.gov/summary/summary.cgi?cid=6112
  8. Available from: http://toxnet.nlm.nih. gov/cgi-bin/sis/search2/r?dbs+hsdb:@term +@rn+@rel+1077-28-7
  9. Bansal D, Badhan Y, Gudala K, Schifano F. Ruboxistaurin for the treatment of diabetic peripheral neuropathy: a systematic review of randomized clinical trials. Diabetes Metab J 2013; 37: 375-84.
  10. Barbiroli B, Medori R, Tritschler H.J, Iotti S. Thioctic acid stimulates muscle ATP production in patients with type-2-diabetes and diabetic polyneuropathy. Diabetes Stoffwechsel 1996; 5 (Suppl. 3): 71-6.
  11. Bierhaus A, Chevion S, Chevion M et al. Advanced glycation end productinduced activation of NF-kB is suppressed by alpha - lipoic acid in cultured endothelial cells. Diabetes 1997; 46: 1481-90.
  12. Borcea V, Nourooz-Zadeh J, Wolff S.P et al. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med 1999; 26: 1495-500.
  13. Boulton A.J, Kempler P, Ametov A, Ziegler D. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev 2013; 29: 327-33.
  14. Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009; 32: 1256-60.
  15. Callaghan B.C, Little A.A, Feldman E.L, Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543.
  16. Cameron N.E, Jack A.M, Cotter M.A. Effect of alpha - lipoic acid on vascular responses and nociception in diabetic rats. Free Radic Biol Med 2001; 31: 125-35.
  17. Carlson D.A, Smith A.R, Fischer S.J et al. The plasma pharmacokinetics of R-(+)-lipoic acid administered as sodium R-(+)-lipoate to healthy human subjects. Altern Med Rev 2007; 12: 343-51.
  18. Coppey L.J, Gellett J.S, Davidson E.P et al. Effect of antioxidant treatment of streptozotocin - induced diabetic rats on endoneurial blood flow, motor nerve conduction velocity, and vascular reactivity of epineurial arterioles of the sciatic nerve. Diabetes 2001; 50: 1927-37.
  19. Coppini D.V, Bowtell P.A, Weng C et al. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000;53:519-23.
  20. Davis T.M, Yeap B.B, Davis W.A, Bruce D.G. Lipid - lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008; 51: 562-6.
  21. Evans J.L, Goldfine I.D. Alpha - lipoic acid: a multifunctional antioxidant that improves insulin sensitivity in patients with type 2 diabetes. Diabetes Technol Ther 2000; 2: 401-13.
  22. Ewing D.J, Martyn C.N, Young R.J, Clarke B.F. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care 1985; 8: 491-8.
  23. Forsblom C.M, Sane T, Groop P.H et al. Risk factors for mortality in Type II (non - insulin - dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998; 4: 1253-62.
  24. Galer B.S, Gianas A, Jensen M.P. Painful diabetic neuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 2000; 47: 123-8.
  25. Garrett N.E, Malcangio M, Dewhurst M, Tomlinson D.R. Alpha-Lipoic acid corrects neuropeptide deficits in diabetic rats via induction of trophic support. Neurosci Lett 1997; 222: 191-4.
  26. Haak E, Usadel K.H, Kusterer K et al. Effects of alpha - lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000; 108: 168-74.
  27. Haak E.S, Usadel K.H, Kohleisen M et al. The effect of alpha - lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res 1999; 58: 28-34.
  28. Han T, Bai J, Liu W, Hu Y. A systematic review and meta - analysis of alpha - lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol 2012; 167: 465-71.
  29. Heitzer T, Finckh B, Albers S et al. Beneficial effects of alpha - lipoic acid and ascorbic acid on endothelium - dependent, nitric oxide - mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med 2001; 31: 53-61.
  30. Hoffman M, Zimmer G. Lipoate prevention of diabetic microangiopathy. In: Fuchs J, Packer L, Zimmer G, editors. Lipoic acid in health and disease. New York: Marcel Decker, 1997; p. 168-74.
  31. Hofmann M.A, Schiekofer S, Isermann B et al. Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative - stress sensitive transcription factor NF-kappa B. Diabetologia 1999; 42: 222-32.
  32. Hofmann M.A, Schiekofer S, Kanitz M et al. Insufficient glycemic control increases nuclear factor - kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care 1998; 21: 1310-6.
  33. Hurdag C, Ozkara H, Citci S et al. The effects of alpha - lipoic acid on nitric oxide synthetase dispersion in penile function in streptozotocin - induced diabetic rats. Int J Tissue React 2005; 27: 145-50.
  34. Jacob S, Henriksen E.J, Tritschler H.J et al. Improvement of insulin - stimulated glucose - disposal in type 2 diabetes after repeated parenteral administration of thioctic acid. Exp Clin Endocrinol Diabetes 1996; 104: 284-8.
  35. Jacob S, Rett K, Henriksen E.J, Haring H.U. Thioctic acid - effects on insulin sensitivity and glucose - metabolism. Biofactors 1999; 10: 169-74.
  36. Keegan A, Cotter M.A, Cameron N.E. Corpus cavernosum dysfunction in diabetic rats: effects of combined alphalipoic acid and gamma - linolenic acid treatment. Diabetes Metab Res Rev 2001; 17: 380-6.
  37. McIlduff C.E, Rutkove S.B. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic olyneuropathy. Ther Clin Risk Manag 2011; 7: 377-85.
  38. Mijnhout G.S, Kollen B.J, Alkhalaf A et al. Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta - analysis of randomized controlled trials. Int J Endocrinol 2012; 2012: 456279.
  39. Mitkov M.D, Aleksandrova I.Y, Orbetzova M.M. Effect of transdermal testosterone or alpha - lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2013; 55: 55-63.
  40. Mitsui Y, Schmelzer J.D, Zollman P.J et al. Alpha - lipoic acid provides neuroprotection from ischemiareperfusion injury of peripheral nerve. J Neurol Sci 1999; 163: 11-16.
  41. Nagamatsu M, Nickander K.K, Schmelzer J.D et al. Lipoic acid improves nerve blood flow, reduces oxidative stress and improves distal nerve conduction in experimental diabetic neuropathy. Diabetes Care 1995; 18: 1160-7.
  42. Nickander K.K, Mc Phee B.R, Low P.A, Tritschler H. Alpha - lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 1996; 21: 631-9.
  43. Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007; 62: 230-8.
  44. Papanas N, Vinik A.I, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol 2011; 7: 682-90.
  45. Papanas N, Ziegler D. Efficacy of a - lipoic acid in diabetic neuropathy. Expert Opin Pharmacother 2014; 15 (18): 2721-31.
  46. Rajamani K, Colman P.G, Li L.P et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780-8.
  47. Rathmann W, Haastert B, Delling B et al. Postmarketing surveillance of adverse drug reactions: a correlational study approach usingmultiple data sources. Pharmacoepidemiol Drug Saf 1998; 7: 51-7.
  48. Reljanovic M, Reichel C, Rett K et al. Treatment of diabetic peripheral neuropathy with the antioxidant thioctic acid (alpha - lipoic acid). A two - year multicenter randomized double blind placebo controlled trial (ALADIN II). Free Rad Res 1999; 31: 171-9.
  49. Resnick H.E, Vinik A.I, Schwartz A.V et al. Independent effects of peripheral nerve dysfunction on lower - extremity physical function in old age. The Women’s Health and Aging Study. Diabetes Care 2000; 23: 1642-7.
  50. Ruessmann H.J. German Society of out patient diabetes centres AND (Arbeitsgemeinschaft niedergelassener diabetologisch ta¨tiger Arzte e.V.). Switching from pathogenetic treatment with alpha - lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real - world study in outpatients. J Diabetes Complications 2009; 23: 174-7.
  51. Ruhnau K-J, Meissner H.P, Finn J.R et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alphalipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999; 16: 1040-3.
  52. Schemmel K.E, Padiyara R.S, D’Souza J.J. Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. J Diabetes Complications 2010; 24: 354-60.
  53. Snedecor S.J, Sudharshan L, Cappelleri J.C et al. Systematic review and meta - analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014; 14: 167-84.
  54. Sola S, Mir M.Q, Cheema F.A et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the irbesartan and lipoic acid in endothelial dysfunction (ISLAND) study. Circulation 2005; 111: 343-8.
  55. Spallone V, Ziegler D, Freeman R et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 2011; 27: 639-53
  56. Stevens M.J, Obrosova I, Cao X et al. Effects of D.L-alpha - lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000; 49: 1006-15.
  57. Teichert J, Hermann R, Ruus P, Preiss R. Plasma kinetics, metabolism, and urinary excretion of alpha - lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 2003; 43: 1257-67.
  58. Teichert J, Tuemmers T, Achenbach H et al. Pharmacokinetics of alpha - lipoic acid in subjects with severe kidney damage and end - stage renal disease. J Clin Pharmacol 2005; 45: 313-28.
  59. Tesfaye S, Boulton A.J, Dyck P.J et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-93.
  60. Tesfaye S, Chaturvedi N, Eaton S.E, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-50.
  61. Tiaka E.K, Papanas N, Manolakis A.C, Maltezos E. The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcers. Int J Burns Trauma 2011; 1: 68-76.
  62. Várkonyi T, Putz Z, Keresztes K et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des 2013; 19: 4981-5007.
  63. Vincent A.M, Hayes J.M, Mc Lean L.L et al. Dyslipidemia - induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009; 58: 2376-85.
  64. Vinik A.I, Maser R.E, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care 2010; 33: 1688-90.
  65. Vinik A.I, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115: 387-97.
  66. Ziegler D, Ametov A, Barinov A et al. Oral treatment with alpha - lipoic acid improves symptomatic diabetic polyneuropathy: The SYDNEY 2 trial. Diabetes Care 2006; 29: 2365-70.
  67. Ziegler D, Hanefeld M, Ruhnau K.J et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha - lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38: 1425-33.
  68. Ziegler D, Hanefeld M, Ruhnau K.J et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha - lipoic acid. A 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999; 22: 1296-301.
  69. Ziegler D, Low P.A, Litchy W.J et al. Efficacy and safety of antioxidant treatment with alpha - lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34: 2054-60.
  70. Ziegler D, Nowak H, Kempler P et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha - lipoic acid: a meta - analysis. Diabet Med 2004; 21: 114-21.
  71. Ziegler D, Rathmann W, Dickhaus T, KORA Study Group. Prevalence of polyneuropathy in pre - diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31: 464-9.
  72. Ziegler D, Schatz H, Conrad F et al. Effects of treatment with the antioxidant alpha - lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997; 20: 369-73.
  73. Ziegler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab Res Rev 2008; 24 (Suppl. 1): S52-7.
  74. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat Endocrinol 2004; 3: 173-89.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2015

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).